ZIOPHARM Oncology, Inc. (ZIOP) Posts Narrower than Expected Q3 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts ZIOP Hot Sheet
Price: $0.87 --0%
Financial Fact:
Net income (loss): -10.85M
Today's EPS Names:
LTBR, AES, SYRS, More
Financial Fact:
Net income (loss): -10.85M
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) reported Q3 EPS of ($0.01), $0.23 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $200 thousand versus the consensus estimate of $120 thousand.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Calix, Inc. (CALX) Tops Q3 EPS by 3c; offers guidance
- Hinge Health, Inc. (HNGE) Tops Q3 EPS by 6c, raises Guidance
- Ichor (ICHR) Tops Q3 EPS by 18c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
